CD163 and breast cancer: However, high levels of CD163 GEX in synchronous LNM associated with shorter OS from the initial breast cancer diagnosis (P = 0.008, estimated median OS from PT diagnosis; 6.6 years, 4.3–8.9 95% CI versus 9.6 years 8.3–11.0 95% CI, respectively; Fig. 5B).